Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Haematologica. 2019 Jul;104(7):1322-1331. doi: 10.3324/haematol.2018.215152. Epub 2019 Jun 20.
In the USA and other western nations, respiratory syncytial virus is one of the most commonly encountered respiratory viruses among patients who have been diagnosed with a hematologic malignancy or who have undergone a stem cell transplant. Multiple studies have been performed to evaluate the complications associated with respiratory syncytial virus infections. Other studies have evaluated therapeutic agents and strategies in which these agents can be used. There have also been numerous reports of outbreaks in bone marrow transplant units and oncology wards, where infection control measures have been invaluable in controlling the spread of disease. However, despite these novel approaches, respiratory syncytial virus continues to be potentially fatal in immunocompromised populations. In this review, we discuss the incidence of respiratory syncytial viral infections, risk factors associated with progression from upper respiratory tract infection to lower respiratory tract infection, other complications and outcomes (including mortality), management strategies, and prevention strategies in patients with a hematologic malignancy and in hematopoietic cell transplant recipients.
在美国和其他西方国家，呼吸道合胞病毒是诊断为血液系统恶性肿瘤或接受过干细胞移植的患者中最常见的呼吸道病毒之一。已经进行了多项研究来评估与呼吸道合胞病毒感染相关的并发症。其他研究评估了治疗剂以及可以使用这些治疗剂的策略。骨髓移植病房和肿瘤病房也有许多呼吸道合胞病毒爆发的报告，在这些病房中，感染控制措施对于控制疾病的传播非常有价值。然而，尽管采取了这些新方法，呼吸道合胞病毒在免疫功能低下的人群中仍然具有潜在的致命性。在这篇综述中，我们讨论了呼吸道合胞病毒感染的发生率、从上呼吸道感染进展为下呼吸道感染的相关风险因素、其他并发症和结果（包括死亡率）、血液系统恶性肿瘤患者和造血细胞移植受者的管理策略和预防策略。
Zotero 插件